SCHEMBL24258081

SCHEMBL24258081

O=C(CCl)Nc1ccc(-c2noc(Cc3ccc(Cl)c(Cl)c3)n2)cn1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERCC1 P07992 1/20 0.45
ERCC4 Q92889 1/20 0.45
MAPK1 P28482 4/20 0.42
TSHR P16473 3/20 0.42
TDP1 Q9NUW8 2/20 0.42
GAA P10253 2/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
S1PR3 Q99500 1/20 0.39
KMT2A Q03164 2/20 0.39
LMNA P02545 2/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
MEN1 O00255 1/20 0.39
SMPD1 P17405 1/20 0.38
SMN1; SMN2 Q16637 4/20 0.38
ALOX15 P16050 1/20 0.38
FFAR1 O14842 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26004989 0.91 ERCC1 (0.44) ERCC1ERCC4MAPK1TSHRTDP1
SCHEMBL26004922 0.85 ABL1 (0.44) ERCC1ERCC4MAPK1TSHRTDP1
SCHEMBL24258089 0.82 ERCC1 (0.45) ERCC1ERCC4MAPK1TSHRTDP1
SCHEMBL24258085 0.81 TLR9 (0.43)
SCHEMBL24258080 0.80 ERCC1 (0.56) ERCC1ERCC4MAPK1TSHRTDP1
SCHEMBL24258075 0.79 ERCC1 (0.52) ERCC1ERCC4MAPK1TSHRTDP1
SCHEMBL24258031 0.78 ERCC1 (0.41) ERCC1ERCC4MAPK1TSHRTDP1
SCHEMBL26006994 0.78 ERCC1 (0.36) ERCC1ERCC4MAPK1TSHRTDP1
SCHEMBL24258029 0.77 ERCC1 (0.50) ERCC1ERCC4MAPK1TSHRTDP1
SCHEMBL26004923 0.77 L3MBTL1 (0.50) ERCC1ERCC4MAPK1TSHRTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230265082-A1 SUBSTITUTED 1,2,4-OXADIAZOLES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. 2023-08-24 US disclosed
US-20230265082-A1 SUBSTITUTED 1,2,4-OXADIAZOLES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. 2023-08-24 US disclosed
WO-2022035805-A1 SUBSTITUTED 1,2,4-OXADIAZOLES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230265082-A1 SUBSTITUTED 1,2,4-OXADIAZOLES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 USP28, USP1, USP18 ERCC1 2832/4885ERCC4 1843/4885MAPK1 829/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.